Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)
Key features and details
- Cell permeable, irreversible pan-caspase inhibitor
- CAS Number: 187389-52-2
- Soluble in DMSO to 20 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor -
製品の詳細
Cell permeable, irreversible pan-caspase inhibitor -
別名
- Z-VAD-FMK (cell permeable)
-
生理活性の詳細
A cell-permeable, irreversible, pan-caspase inhibitor. Inhibits caspase processing and apoptosis induction in tumor cells in vitro. Once in the cell, endogenous esterase activity hydrolyzes the methyl groups to form the biologically active form. Therefore, when using with isolated, purified or recombinant caspase enzymes, pre-treatment with an esterase is required.
-
CAS 番号
187389-52-2 -
構造式
製品の特性
-
分子量
467.49 -
分子式
C22H30FN3O7 -
配列
VAD (Modifications: N-terminal benzyloxycarbonyl; C-terminal FMK; Asp-3 = Asp(OMe)) -
PubChem 登録番号
5497173 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 20 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
FCC(=O)C(CC(=O)OC)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C -
由来
Synthetic
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120487の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| 特記事項 |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
画像
-
Chemical Structure - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)2D chemical structure image of ab120487, Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor
-
Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)HeLa cells were incubated at 37°C for 1h with vehicle control (0 µM) and different concentrations of Z-VAD(OMe)-FMK (ab120487). After this incubation 10 µM of camptothecin (ab120115) was added to all samples and the cells were incubated for further 24h. Increased expression of full length PARP (ab37722) in camptothecin induced apoptotic HeLA cells correlates with an increase in Z-VAD(OMe)-FMK concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab37722 at 1 µg /ml and ab8227 at 1 µg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution.
-
Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)Titration of the Caspase inhibitor Z-VAD(OMe)-FMK (ab120487) (duplicates; +/- SD). -
Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (ab120487)
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (20)
ab120487 は 20 報の論文で使用されています。
- Sarkar A et al. Early loss of endogenous NAD+ following rotenone treatment leads to mitochondrial dysfunction and Sarm1 induction that is ameliorated by PARP inhibition. FEBS J 290:1596-1624 (2023). PubMed: 36239430
- Rios-Szwed DO et al. FAM111A regulates replication origin activation and cell fitness. Life Sci Alliance 6:N/A (2023). PubMed: 37793778
- Bharti V et al. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Rep 41:111826 (2022). PubMed: 36543138
- Henning Y et al. Hypoxia aggravates ferroptosis in RPE cells by promoting the Fenton reaction. Cell Death Dis 13:662 (2022). PubMed: 35906211
- Fan Z et al. Neuronal MD2 induces long-term mental impairments in septic mice by facilitating necroptosis and apoptosis. Front Pharmacol 13:884821 (2022). PubMed: 36016572
